Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00000280
DRKS00000280
Completed
Phase 1

Impact of selective serotonine re-uptake-inhibitors on acid sphingomyelinase activity in peripheral leucocytes of healthy adult male volunteers - ASM-Activity

niversitätsklinikum Erlangen Psychiatrische und Psychotherapeutische Klinik0 sites18 target enrollmentJanuary 4, 2010
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsF32F33Depressive episodeRecurrent depressive disorder

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
F32
Sponsor
niversitätsklinikum Erlangen Psychiatrische und Psychotherapeutische Klinik
Enrollment
18
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 4, 2010
End Date
September 28, 2010
Last Updated
last year
Study Type
Interventional
Sex
Male

Investigators

Sponsor
niversitätsklinikum Erlangen Psychiatrische und Psychotherapeutische Klinik

Eligibility Criteria

Inclusion Criteria

  • •Able to understand the risks involved in their participation in the trial
  • •Able to understand and follow explanations and instructions of the Investigator and other study personnel
  • •Ability to take part in the weekly visits
  • •Given informed consent

Exclusion Criteria

  • •Known allergy to any of the study drugs
  • •Significant psychiatric or neurological disorder
  • •Addiction to drugs or alcohol (except to coffeine or nicotine)
  • •Inmate at a psychiatric hospital
  • •Significant cardiovascular, gastrointestinal, hepatic or renal disorder
  • •Significant abnormalities in the ECG, specifically QTc prolongation \>440 msec
  • •Values outside the normal range in routine lab assessments
  • •Participation in another clinical trial in the preceding 3 months
  • •Administration of any psychotropic medication in the preceding 30 days

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
Effects of selective serotonin re-uptake inhibition on MOrbidity, mOrtality and mood in Depressed Heart Failure patientsHeart failure and co-morbid depressionMental and Behavioural Disorders
ISRCTN33128015German Federal Ministry of Education and Research (Bundesministerium Für Bildung und Forschung [BMBF]) (Germany)414
Active, not recruiting
Not Applicable
Effects of an antidepressant drug on morbidity, mortality and mood in Depressed Heart Failure patients
EUCTR2007-006609-25-DEJulius Maximilians Universität Würzburg
Active, not recruiting
Phase 1
Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase II trialgastroesophageal cancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2022-001989-36-ATMed. Univ. Wien, Klinik f. Innere Med I, Onkologie35
Not yet recruiting
Not Applicable
Circadian mechanisms for selective serotonin reuptake inhibitor treatment responsesdepressionMental Health - Depression
ACTRN12621000581864Monash University36
Completed
Not Applicable
Effect of serotonin-norepinephrine reuptake inhibitor on functional gastrointestinal disorder and evaluation of the brain function.
JPRN-UMIN000023995Shimane University Faculty of Medicine Department of Psychiatry200